Securinine bolsters anti-tumor immunity by promoting CD8⁺ T cell activation.
Securinine (SEC) is a natural alkaloid isolated from Flueggea suffruticosa, which can suppress tumor growth of some types.
APA
Gui L, Song W, et al. (2026). Securinine bolsters anti-tumor immunity by promoting CD8⁺ T cell activation.. Cancer treatment and research communications, 47, 101120. https://doi.org/10.1016/j.ctarc.2026.101120
MLA
Gui L, et al.. "Securinine bolsters anti-tumor immunity by promoting CD8⁺ T cell activation.." Cancer treatment and research communications, vol. 47, 2026, pp. 101120.
PMID
41653874
Abstract
Securinine (SEC) is a natural alkaloid isolated from Flueggea suffruticosa, which can suppress tumor growth of some types. T cells play a critical role in anti-tumor function. However, whether SEC mediates T cell-mediated anti-tumor effects remains unknown. Here, we found that SEC treatment suppressed tumor growth and improved survival in tumor-bearing mice in vivo. SEC promotes the percentage of IFN-γCD8 T cell and TNF-αCD8 T cell in tumor microenvironments. SEC promoted T cell-mediated cytotoxicity in B16F10-OVA and OT-I co-culture systems. The anti-tumor function of SEC was abrogated after depleting CD8 T cells in tumor-bearing mice. Mechanistically, SEC promoted T cell receptor (TCR) activation, increased IL-2 and IFN-γ production, and enhanced mitochondrial metabolism in CD8 T cells. Additionally, SEC combination with anti-PD-1 suppressed tumor growth and improved survival in tumor-bearing mice. Thus, SEC enhances anti-tumor immunity by promoting CD8 T cell activation, suggesting its potential role in tumor immunotherapy.
같은 제1저자의 인용 많은 논문 (5)
- Abexinostat, a histone deacetylases inhibitor, for patients with relapsed or refractory follicular lymphoma: a multi-center, single-arm phase 2 study.
- Gossypol suppresses tumorigenesis through inhibition of multiple deubiquitinating enzymes.
- CHST1 as a prognostic-related biomarker in gastric cancer correlating with immune infiltration.
- Case report: Complete response of an anaplastic thyroid carcinoma patient with Q61R/ D594N mutations to the triplet of dabrafenib, trametinib and PD-1 antibody.
- Genioplasty and chin augmentation with Medpore implants: a report of 650 cases.